Excellent Results and Minimal Complications of Total Hip Arthroplasty in Sickle Cell Hemoglobinopathy at Mid-Term Follow-Up Using Cementless Prosthetic Components

被引:36
作者
Issa, Kirnon [1 ]
Naziri, Qais [1 ,2 ]
Maheshwari, Aditya V. [2 ]
Rasquinha, Vijay J. [2 ]
Delanois, Ronald E. [1 ]
Mont, Michael A. [1 ]
机构
[1] Sinai Hosp, Rubin Inst Adv Orthoped, Ctr Joint Preservat & Replacement, Baltimore, MD 21215 USA
[2] Suny Downstate Med Ctr, Dept Orthopaed, Brooklyn, NY 11203 USA
关键词
total hip arthroplasty; sickle cell hemoglobinopathy; clinical outcomes; Harris hip scores; implant survivorship; FEMORAL-HEAD; NATURAL-HISTORY; ASYMPTOMATIC OSTEONECROSIS; GENETIC-VARIANTS; DISEASE; REPLACEMENT; MANAGEMENT; ANEMIA; ADULTS; NECROSIS;
D O I
10.1016/j.arth.2013.03.017
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
The purpose of this study was to compare the outcomes of cementless primary total hip arthroplasty (THA) in sickle cell patients compared to the remaining cohort of osteonecrosis patients who did not have this disease. Thirty-two sickle cell patients (42 hips) who had a mean age of 37 years and mean follow-up of 7.5 years (range, 5-11 years) were compared to 87 non-sickle cell osteonecrosis patients (102 hips) who had mean age of 43 years and mean follow-up of 7 years (range, 3-10.5 years). Outcomes evaluated included implant survivorship, Harris hip scores, complication rates, radiographic outcomes, and Short Form-(SF-36) health questionnaire. There were no significant differences in aseptic implant survivorship (95 vs. 97%), Harris. hip scores (87 vs. 88 points), SF-36 score, or radiographic findings between the two patient cohorts. In light of these findings, we believe that the outcomes of THA improved in sickle cell patients with optimized medical management and the use of cementless prosthetic devices. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:1693 / 1698
页数:6
相关论文
共 39 条
[1]   HIP-ARTHROPLASTY IN PATIENTS WITH SICKLE-CELL HEMOGLOBINOPATHY [J].
ACURIO, MT ;
FRIEDMAN, RJ .
JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 1992, 74 (03) :367-371
[2]   Total hip replacement in sickle cell disease [J].
Al-Mousawi, F ;
Malki, A ;
Al-Aradi, A ;
Al-Bagali, M ;
Al-Sadadi, A ;
Booz, MMY .
INTERNATIONAL ORTHOPAEDICS, 2002, 26 (03) :157-161
[3]  
Arlet J, 1977, Chir Narzadow Ruchu Ortop Pol, V42, P269
[4]   TOTAL HIP-ARTHROPLASTY IN PATIENTS WHO HAVE SICKLE-CELL HEMOGLOBINOPATHY [J].
BISHOP, AR ;
ROBERSON, JR ;
ECKMAN, JR ;
FLEMING, LL .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1988, 70A (06) :853-855
[5]   The Frank Stinchfield Award The Impact of Socioeconomic Factors on Outcome After THA A Prospective, Randomized Study [J].
Butler, R. Allen ;
Rosenzweig, Seth ;
Myers, Leann ;
Barrack, Robert L. .
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2011, 469 (02) :339-347
[6]   NECROSIS OF FEMORAL HEAD ASSOCIATED WITH SICKLE-CELL ANEMIA AND ITS GENETIC VARIANTS - A REVIEW OF LITERATURE AND STUDY OF 13 CASES [J].
CHUNG, SMK ;
RALSTON, EL .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1969, A 51 (01) :33-+
[7]  
CHUNG SMK, 1978, CLIN ORTHOP RELAT R, P158
[8]   TOTAL REPLACEMENT OF THE HIP FOR AVASCULAR NECROSIS IN SICKLE-CELL DISEASE [J].
CLARKE, HJ ;
JINNAH, RH ;
BROOKER, AF ;
MICHAELSON, JD .
JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 1989, 71 (03) :465-470
[9]  
dos Santos Jean Leandro, 2011, Cardiovascular & Hematological Agents in Medicinal Chemistry, V9, P113
[10]   Advances Reshaping Sickle Cell Therapy [J].
Friedrich, M. J. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (03) :239-242